GE biopharm
GE biopharm

Companies to integrate Emerson’s DeltaV distributed control system with GE’s technologies for manufacture of monoclonal antibodies, vaccines and other biologics 

Collaboration will help drive improvements in productivity 


CHALFONT ST. GILES, UK and AUSTIN, TEXAS, USA  (November 16, 2015)  –​ GE Healthcare’s Life Sciences business andEmerson Process Management, a global business of Emerson (NYSE: EMR), today announced a collaboration aimed at increasing productivity and improving efficiency in the production of biopharmaceuticals such as monoclonal antibodies and vaccines. The two companies will collaborate to integrate Emerson’s DeltaV™ distributed control system with GE Healthcare’senterprise offerings and start-to-finish technologies for the global biomanufacturing industry. The first DeltaV-driven GE Healthcare installation, which is expected to be complete before the end of the year, will be a FlexFactory™, GE’s integrated manufacturing platform based on single-use technologies.   

 

Biopharmaceutical manufacturers are increasingly looking to automate production processes, driven by the industry need to increase efficiency and reduce costs. GE’s start-to-finish portfolio of single-use bioprocessing technologies already allows manufacturers to reduce set-up times and increase manufacturing flexibility. Emerson’s DeltaV system, which uses predictive technologies to connect people, processes and production, enables remote monitoring and control from multiple locations across a company’s network and is already widely used in the pharmaceutical industry. The DeltaV system will be offered as an automation control platform for GE’s single-use bioprocessing offerings.

 

Emmanuel Ligner, Global Commercial Manager, BioProcess, GE Healthcare Life Sciences, said: “Healthcare providers and the biopharmaceutical industry are facing enormous pressures.  Emerson and GE share a vision that an integrated and automated approach to manufacturing has the potential to help drive improvements in production efficiency of these life-saving medicines.  This collaboration with Emerson, combined with our depth and breadth of expertise in start-to-finish technologies for bioprocessing, promises to bring real benefits to our customers and to healthcare providers worldwide.”

 

”We believe that the combination of Emerson’s automation technologies and the GE FlexFactory will offer superior process performance, consistency of product, and reduced validation time,” said Jerry Brown, senior vice president of industry solutions for Emerson Process Management.  “This collaboration will support more predictable processes that eliminate unnecessary work, which translates into a reduced time to market for our customers.”

 

About GE Healthcare

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world.  GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at www.gehealthcare.com. 

 

About Emerson Process Management

Emerson Process Management (www.EmersonProcess.com), an Emerson business, is a leader in helping businesses automate their production, processing and distribution in the chemical, oil and gas, refining, pulp and paper, power, water and wastewater treatment, mining and metals, food and beverage, life sciences and other industries. The company combines superior products and technology with industry-specific engineering, consulting, project management and maintenance services. Its brands include Bettis™, DeltaV™, Fisher™, Micro Motion™, Ovation™ and Rosemount™.

Please enable JavaScript to use this website.